Salix Pharmaceuticals Ltd. develops and commercializes prescription drugs and medical devices used in the treatment of gastrointestinal diseases, endocrinology, hepatology, colorectal surgery, and internal medicine. It offers Anusol, Apriso, Colazal, Deflux, Diuril, Fenoglide, MoviPrep, Pepcid, Solesta, and Zegerid. The company was founded by randy W. Hamilton and Lorin K. Johnson in1989 and is headquartered in Bridgewater, NJ.

Signal Pharmaceuticals is a biopharmaceutical company that was founded by David Anderson (Senior VP & Head of Research), Alan Lewis (CEO), Mark Carmen, and Jackie Johnson and is based in California. It was acquired by Celgene in 2009

Replimune Ltd., a subsidiary of Replimune Group, Inc., is a British company located in Abingdon involved in commercial physical and biological research. It was founded in 2015.\nThe company says this about itself: The company was incorporated on 18 March 2015 as an investor-funded research and development company, based in the UK and with a US corporate parent and support office. The company specializes in developing an emerging class of cancer therapeutics, known as oncolytic immunotherapy.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

T.C.D. SpA is an Italian private company located in Latina. The firm wholesales computers.

Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

Allogene Therapeutics is a clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

Beijing Haoer Biotechnology Co., Ltd., established on 2018-03-01, Business scope includes biotechnology development,technical consulting,Technical Services,technology transfer,Technology Promotion;Import and export;Technology Import and Export;Agent import and export;software development;Business Management Consulting,health management(Except for medical treatment activities subject to approval),Health Advisory(Except for medical treatment activities subject to approval);sell cosmetics,Iclass of medical devices.(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

Zhongao Biomedical Technology (Guangdong) Co., Ltd., established on 2018-11-15, Business scope includes general items:Medical Research and Experimental Development;Engineering and Technology Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Natural science research and experimental development;R&D and application of cell technology;Domestic trade agent;trade broker;internet sales(Except for products that require a license for sale);Sales of Class I Medical Devices;Wholesale of protective equipment for medical staff;Retailing of protective equipment for healthcare workers;Sales of hygiene products and single-use medical products;Class I Medical Device Leasing;Medical Mask Retail;Import and export agency;Import and export;Technology Import and Export.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)[The above business scope does not involve human stem cells,Development and application of genetic diagnosis and treatment technology;Steaming of Chinese Herbal Pieces,saute,broil,The application of calcining and other processing technologies and the production of secret prescription products of Chinese patent medicines;Research and development of rare and unique precious varieties in China,farming,Planting and production of related propagating material(including farming,animal husbandry,Good Genes of Aquaculture)][The above business scope involves:Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval)](The above projects do not involve special management measures for foreign investment access)

Piramal Enterprises Ltd. engages in the business of pharmaceuticals and provision of financial services. It operates through the following segments: Pharmaceuticals Manufacturing and Services, Financial Services, and Healthcare Insights and Analytics. The Pharmaceuticals Manufacturing and Services segment operates through the following divisions: Pharma Solutions, Critical Care, Consumer Products Services and Imaging. The Financial Services segment offers a complete suite of financial products to meet the diverse needs of its customers. The Healthcare Insights and Analytics segment provides indispensable insights to life sciences companies as well as healthcare providers and payers through a variety of high value-added data and analytics, research reports, and knowledge-based services. The company was founded on April 26, 1947 and is headquartered in Mumbai, India.

Scandion Oncology develops drugs that specifically target chemotherapy resistance mechanisms. Improving the outcome and quality of life for cancer patients is their mission. Drug resistance is one of the most significant challenges for successful medical treatment in oncology. Right now, half of all cancer patients fail chemotherapy. Although many cancer patients initially benefit from chemotherapy, a large proportion develop resistance to chemotherapy drugs. Few of these patients survive.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Seattle Genetics is a clinical-stage biotechnology company that focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington.

Beijing Solarbio Science & Technology Co., Ltd. is a private company headquartered in China that manufactures biological reagents and kits.

The history of Self-screen is a track record in translational science. The company was founded in 2008 to advance the implementation of scientific discoveries in the field of cancer screening into routine practice. Our dedication is towards the development and clinical application of molecular assays for the early detection of cancer, thereby to the benefit of patients around the world. Currently, the company’s main focus is on cervical cancer screening and prevention. The company has two clinically validated assays on the market. We strive towards all-molecular screening to ensure objectivity, reproducibility and high-throughput possibilities. Our research and development pipeline currently focuses on the extension of our science towards other sample types, like urine, and towards other cancer types.

Attobio Pharmaceutical (Suzhou) Co. Ltd. engages in the development of biomedical technology and products. Its business activities include the innovation of products designed to improve the level of preventive medicine and early detection of disease to provide accurate diagnostic techniques, and the import and export of biological reagents and biotechnology. The company was founded by Xiao Jia Chang on May 7, 2012 and is headquartered in Suzhou, China.

Foshan Rexu Biotechnology Co., Ltd., established on 2018-01-12, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Engineering and Technology Research and Experimental Development;Technology intermediary service;Sales of Class II Medical Devices;Sales of Class I Medical Devices;Production of Class I Medical Devices[Branch operation].(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:pharmaceutical production[Branch operation];Production of hygiene products and single-use medical products[Branch operation];Production of Class II Medical Devices[Branch operation].(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Pharmacia & Upjohn Co. LLC, a subsidiary of Pfizer Inc., is a company headquartered in Bingham Farms, MI, that manufactures and supplies pharmaceutical goods.

Trustees of Dartmouth College, part of Dartmouth College, is a company headquartered in Hanover, NH. The firm operates higher education institutes. It was founded in 1769.